Stability of Triamcinolone Added in Three Oral Liquid Syrups

경구용 시럽제 중 Triamcinolone의 안정성 연구

  • Yoon, Hee-Young (Graduate School of Clinical Health Sciences, Ewha Womans University) ;
  • Lee, Byung-Koo (Graduate School of Clinical Health Sciences, Ewha Womans University) ;
  • Gwak, Hye-Sun (Graduate School of Clinical Health Sciences, Ewha Womans University)
  • 윤희영 (이화여자대학교 임상보건과학대학원) ;
  • 이병구 (이화여자대학교 임상보건과학대학원) ;
  • 곽혜선 (이화여자대학교 임상보건과학대학원)
  • Received : 2012.03.02
  • Accepted : 2012.05.22
  • Published : 2012.06.30

Abstract

The stability of triamcinolone in three kinds of oral liquid syrups at 4 and $25^{\circ}C$ was studied for 21 days. Twenty tablets of 4 mg triamcinolone were mixed with 100 mL of each oral liquid syrup, which is Levotuss$^{(R)}$Syrup (levodropropizine 6 mg/mL), Ucerax$^{(R)}$Syrup (hydroxyzine 2 mg/mL), and Xyzal$^{(R)}$Liquid (levocetirizine 0.5 mg/mL). The chromatographic analysis after deliberate degradation showed no evidence of any breakdown product likely to interfere with the chromatographic peak of the parent substance. The relationship between triamcinolone concentrations and peak areas was linear from 50 to 1000 ${\mu}g/mL$ ($r^2$ = 0.9998). The analysis method was precise, with coefficients of variation no greater than 5.4%. Triamcinolone was stable for up to 14 and 21 days in Levotuss$^{(R)}$Syrup at 25 and $4^{\circ}C$, respectively; in Ucerax$^{(R)}$Syrup and Xyzal$^{(R)}$Syrup, it was stable for at least 21 days at both temperatures. The percentages of initial triamcinolone concentration remaining after 21 days were $72.3{\pm}3.2$ and $94.9{\pm}6.0%$ and $93.2{\pm}4.9$ and $92.4{\pm}5.7%$, and $92.6{\pm}1.2$ and $92.7{\pm}2.2%$ in Levotuss$^{(R)}$Syrup, Ucerax$^{(R)}$Syrup, and Xyzal$^{(R)}$Syrup at 25 and $4^{\circ}C$, respectively. The pH variations of all test solutions were within 0.8. Based on the results, it was concluded that triamcinolone in three oral liquid syrups which are Levotuss$^{(R)}$syrup, Ucerax$^{(R)}$syrup and Xyzal$^{(R)}$syrup was chemically and physically stable in both states of refrigeration and room temperature for at least 14 days.

Keywords

References

  1. Doggrell SA. Triamcinolone: new and old indications. Expert Opin Pharmacother 2001; 2: 1177-1186. https://doi.org/10.1517/14656566.2.7.1177
  2. Charles FL, Lora LA, Morton PG, et al., Drug Information Handbook. 17th ed. Hudson: Lexi-Comp; 2008.
  3. http://www.drugs.com/triamcinolone.html
  4. McCrea J, Rappaport P, Stansfield S, et al., Extemporaneous oral liquids formulation guidelines. On Continuing Practice 1991; 18: 22-24.
  5. Mistry B, Samuel L, Bowden S, et al., Simplifying oral drug therapy for patients with swallowing difficulties. Pharm J 1995; 254: 808-809.
  6. Paradiso LM, Roughead EE, Gilbert AL, et al., Crushing or altering medications: what's happening in residential aged-care facilities? Australas J Ageing 2002; 21: 123-127. https://doi.org/10.1111/j.1741-6612.2002.tb00432.x
  7. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104: 607-609.
  8. Nahata MC, Morosco RS, Leguire LE. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus 2000; 37: 333-337.
  9. Steele RW, Estrada B, Begue RE. A double-blind taste comparison of pediatric antibiotic suspensions. Clin Pediatr 1997; 36: 193-199. https://doi.org/10.1177/000992289703600402
  10. Hendeles L. Selecting a systemic corticosteroid for acute asthma in young children. J Pediatr 2003; 142: S40-S44. https://doi.org/10.1067/mpd.2003.25
  11. www.fda.gov/ohrms/dockets/98fr/cd0560.pdf, 2006
  12. Zuckner J, Ramsey RH, Caciolo C, et al., Triamcinolone therapy in rheumatoid arthritis. Ann Rheum Dis 1958; 17: 398-405. https://doi.org/10.1136/ard.17.4.398
  13. Isa JM, Wong GK, Teraoka SS, et al., Parental Pediatric Corticosteroid Preferences. Am J Emerg Med 2001; 19: 29-31. https://doi.org/10.1053/ajem.2001.20025
  14. Kommanaboyina B, Rhodes CT. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm 1999; 25: 857-868. https://doi.org/10.1081/DDC-100102246
  15. Trissel LS. Handbook of injectable drugs. 13th ed. Bethesda: American Society of Health-System Pharmacists; 2005.
  16. Kamas HT, Shiu G, Shah VP. Validation of bioanalytical methods. Pharm Res 1991;8: 421-426. https://doi.org/10.1023/A:1015882607690
  17. Glass BD, Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Sci 2006; 9: 398-426.
  18. Cisternino S, Schlatter J, Saulnier JL. Stability of fludrocortisone acetate solutions prepared from tablets and powder. Eur J Pharm Biopharm 2003; 55: 209-213. https://doi.org/10.1016/S0939-6411(02)00159-5
  19. Monder C. Stability of corticosteroids in aqueous solutions. Endocrinology 1968; 82: 318-326. https://doi.org/10.1210/endo-82-2-318